Komori
Transgenic Group (2342) · FactRestated

Seasonality with sales concentrated in the second half

First written in FY2017-Q1. 10 of 15 entries say "Restated". Latest entry: FY2024-Q2.

15entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017-Q1 – FY2024-Q22016: 220162017: 320172018: 120182019: 320192020: 220202021: 220212022: 020222023: 22023
Same theme, other companies

The whole theme swung hardest in 2024: 4 of 13 companies on the "Worse" side.

13 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 23 companies compared. The sentences above are computed from all 23.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q2RestatedAnnual report

    「The proportion of overseas projects among contracted projects increased, and the contracted studies also became larger in scale and longer in duration. As a result, although the order backlog at the end of the second quarter was higher year on year, many studies were scheduled for completion from the second half onward, and revenue decreased year on year.」

    The increase in overseas projects and the larger scale and longer duration of contracted studies are reaffirmed as factors resulting in more studies being scheduled for completion and revenue recognition from the second half onward.
  2. FY2024-Q1Concentration of revenue recognition in the second half due to large, long-term studiesAnnual report

    「As the number of contracted studies increased, the proportion of overseas projects rose, and the contracted studies also became larger in scale and longer in duration. As a result, more studies were scheduled for completion from the second half of the current fiscal year onward, and revenue increased only slightly year on year.」

    The increase in the proportion of overseas projects and the larger scale and longer duration of contracted studies led to a situation in which study completions and revenue recognition were concentrated from the second half onward.
  3. FY2021RestatedAnnual report

    「Since launching this business in November 2017, companies that joined the group through M&A have made a steady contribution to profit and have also helped level out the group's earnings structure, which had previously been weighted toward the second half.」

    The explanation that profit contributions from M&A-acquired companies, including through the TGBS business, level out the earnings structure that had been weighted toward the second half is being reaffirmed.
  4. FY2021-Q3RestatedAnnual report

    「The drug discovery support business is subject to substantial seasonal fluctuations, and the group's revenue tends to be concentrated in the second half, particularly the fourth quarter.」

    The seasonality of group revenue, including the drug discovery support business, being concentrated in the second half, particularly the fourth quarter, is being reaffirmed.
  5. FY2020RestatedAnnual report

    「Companies that joined the group through M&A made a steady contribution to profit and also helped level out the group's earnings structure, which had previously been weighted toward the second half.」

    The explanation that the profit contribution of M&A-acquired companies leveled out the earnings structure, which had previously been weighted toward the second half, is being reaffirmed.
  6. FY2020-Q3RestatedAnnual report

    「The group's revenue, excluding the TGBS business, is subject to substantial seasonal fluctuations and tends to be concentrated in the second half, particularly the fourth quarter.」

    For existing businesses excluding the TGBS business, the seasonality of revenue concentration in the second half, particularly the fourth quarter, is being reaffirmed.
  7. FY2020-Q2RestatedAnnual report

    「The group's revenue, excluding the TGBS business, is subject to substantial seasonal fluctuations and tends to be concentrated in the second half, particularly the fourth quarter.」

    For existing businesses excluding the TGBS business, the seasonality of revenue concentration in the second half, particularly the fourth quarter, is being reaffirmed.
  8. FY2019Leveling of the earnings structureAnnual report

    「Companies that joined the group through M&A made a steady contribution to profit and also helped level out the group's earnings structure, which had previously been weighted toward the second half.」

    It is explained that the profit contribution of M&A-acquired companies through the TGBS business leveled out the group's seasonality, which had previously been weighted toward the second half.
  9. FY2019-Q3Clarification of the scope of seasonalityAnnual report

    「The group's revenue, excluding the TGBS business, is subject to substantial seasonal fluctuations and tends to be concentrated in the second half, particularly the fourth quarter.」

    The scope has been clarified: unlike the previous explanation of seasonality, revenue in businesses excluding the TGBS business is concentrated in the second half, particularly the fourth quarter.
  10. FY2018-Q3RestatedAnnual report

    「The group's revenue is subject to substantial seasonal fluctuations and tends to be concentrated in the second half, particularly the fourth quarter.」

    The seasonality of revenue concentration in the second half, particularly the fourth quarter, is reiterated.
  11. FY2018-Q2Further detail on seasonalityAnnual report

    「In the previous consolidated fiscal year, supported by a substantial opening backlog of carried-forward orders, revenue for the cumulative second quarter accounted for 42.8% of full-year consolidated revenue, compared with 32.8% in the consolidated fiscal year before last, meaning that revenue was more concentrated in the first half than in the preceding fiscal year. In the current consolidated fiscal year, although the opening carried-forward backlog was lower than in the previous fiscal year, the order backlog has steadily accumulated, and revenue is expected to be more concentrated in the second half, as in the consolidated fiscal year before last.」

    The background to the expected concentration of revenue in the second half is detailed, including first-half revenue ratios of 42.8% and 32.8% in prior fiscal years.
  12. FY2018-Q1RestatedAnnual report

    「The group's revenue is subject to substantial seasonal fluctuations and tends to be concentrated in the second half of the fiscal year.」

    The seasonality of revenue concentration in the second half is reiterated in the notes.
  13. FY2017-Q3RestatedAnnual report

    「The group's revenue is subject to substantial seasonal fluctuations and tends to be concentrated in the second half of the fiscal year.」

    The seasonality of revenue concentration in the second half is reiterated in the notes.
  14. FY2017-Q2RestatedAnnual report

    「The group's revenue is subject to substantial seasonal fluctuations and tends to be concentrated in the second half of the fiscal year.」

    The seasonality of revenue concentration in the second half is reiterated in the notes.
  15. FY2017-Q1First statedAnnual report

    「The group's revenue is subject to substantial seasonal fluctuations and tends to be concentrated in the second half of the fiscal year.」

    The significant seasonality of revenue, with a structural tendency toward concentration in the second half, is described.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Transgenic Group yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Seasonality with sales concentrated in the second half | TRANSGENIC GROUP INC. (2342) | Komori